ECM
AGN

EagleClaw Capital Management’s Allergan plc AGN Stock Holding History

EagleClaw Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$204K – 114
2017
Q3 		$204K Hold
1,000
– – 0.12% 104
2017
Q2 		$244K Hold
1,000
– – 0.14% 103
2017
Q1 		$238K Hold
1,000
– – 0.14% 101
2016
Q4 		$210K Hold
1,000
– – 0.13% 103
2016
Q3 		$230K Buy
+1,000
New +$244K 0.15% 98

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

EagleClaw Capital Management's AGN Position: Q4 2017 in Review

EagleClaw Capital Management sold out of Allergan plc (AGN) in Q4 2017, closing a stake of 1,000 shares — an estimated $204K sold.

EagleClaw Capital Management first reported a position in AGN in Q3 2016 and held it in 5 quarters. The position peaked at $244K in Q2 2017. 1,048 funds tracked by Wall St. Rank hold AGN as of Q4 2017.

  • EagleClaw Capital Management reported no remaining Allergan plc position as of Q4 2017 after selling out during the quarter.
  • EagleClaw Capital Management sold 1,000 Allergan plc shares in Q4 2017, an estimated $204K.
  • EagleClaw Capital Management first reported a position in Allergan plc in Q3 2016 and held it in 5 quarters.
  • EagleClaw Capital Management's Allergan plc position peaked at $244K in Q2 2017.
  • 1,048 funds tracked by Wall St. Rank held Allergan plc as of Q4 2017.

Based on EagleClaw Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.